WO2013032052A1 - 중간엽 줄기세포 기본 배양 배지 조성방법, 중간엽 줄기세포 기본 배양 배지 및 이를 이용하여 배양분화된 세포치료제 - Google Patents
중간엽 줄기세포 기본 배양 배지 조성방법, 중간엽 줄기세포 기본 배양 배지 및 이를 이용하여 배양분화된 세포치료제 Download PDFInfo
- Publication number
- WO2013032052A1 WO2013032052A1 PCT/KR2011/006582 KR2011006582W WO2013032052A1 WO 2013032052 A1 WO2013032052 A1 WO 2013032052A1 KR 2011006582 W KR2011006582 W KR 2011006582W WO 2013032052 A1 WO2013032052 A1 WO 2013032052A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- medium
- mesenchymal stem
- stem cells
- abm
- culture medium
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/34—Sugars
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
Definitions
- the present invention relates to a mesenchymal stem cell basic culture medium derived from bone marrow and fat, and in particular, mesenchymal stem cells using a conventionally commercialized medium in the process of culturing mesenchymal stem cells derived from bone marrow and fat in vitro.
- mesenchymal stem cells using a conventionally commercialized medium in the process of culturing mesenchymal stem cells derived from bone marrow and fat in vitro.
- the present invention relates to a method for forming a multi-differentiable mesenchymal stem cell basic culture medium, a mesenchymal stem cell basic culture medium, and a cell therapeutic agent cultured using the same.
- stem cells in regenerative medicine using tissue engineering has been proposed as a new field for the treatment of intractable disease.
- the interest in stem cell research is increasing, and stem cells capable of forming tissues through proliferation and differentiation are recognized to be able to solve tissue damage as well as treat most diseases.
- Stem cells have branching ability in undifferentiated state and have the property of differentiating into specific cells under appropriate conditions. Stem cells can be divided into embryonic stem cells and adult stem cells, depending on their origin. Since human embryonic stem cells are obtained from embryos that can occur in human life, they have excellent cell proliferation and differentiation but have bioethical problems. Adult stem cells are limited in their differentiation capacity compared with embryonic stem cells, but cells already existing in various organs of the human body are collected from bone marrow, blood, brain, and skin, and developed into stem cells.
- Mesenchymal stem cells were first isolated from adult bone marrow (Y. Jiang et al ., Nature , 418: 41, 2002) and then mesenchymal stems such as bone marrow from skin, blood vessels, muscle and brain tissue. Cells were identified (JG Toma et al ., Nat. Cell Biol. , 3: 778, 2001; M. Sampaloesi et al ., Science , 301: 487, 2003; Y. Jiang et al ., Hematol ., 30 : 896, 2002). In addition, adipose-derived stem cells, which have differentiation potential as bone marrow, have recently been identified from adipose tissue (B.
- mesenchymal stem cells are very rarely present in adult tissues such as bone marrow and adipose tissue, and these cells have low proliferation rate in undifferentiated state and are difficult to maintain for a long time in undifferentiated state.
- the disadvantage is that it is difficult to do.
- Mammalian cell culture medium consists of about 50 kinds of components, which are largely used for the biosynthesis of cells, the parts used for biological energy metabolism, as a catalyst for various metabolism or physiological phenomena in cells. It can be divided into parts used to control.
- the medium used for cell culture is composed of isotonic solution components, buffer components, nutrients including amino acids, vitamins, and inorganic salts as energy sources, and various other supplements.
- the cell by supplying about 5 to 20% of serum according to the characteristics of the cell, it supplies various hormones, growth factors, fats, and vitamins suitable for cell proliferation, inhibits protease activity, and acts as a buffer for pH control. Promotes the growth and activity of mammalian cells.
- the components constituting the medium for culturing mammalian cells vary depending on the type of medium in terms of concentration as well as its composition. In this way, around 1950 Morgan (Morgan et al .) Made M119 medium based on the composition of the humor and cultured the primary chick (Morgan, et al ., 1950).
- Types of culture media are largely the Minimal essential medium (MEM) (Eagle, 1955), Rosewel Park Memorial Institute (RPMI) -1640 (Moore et al ., 1967), and Dulbecco's modification of Eagle's medium (DMEM) (Dulbecoo, et al. , 1959) and more complex media such as Iscove's modification of DMEM (IMDM), Ham's F-12 (Ham, 1965), and Connaught Medical Research Laboratories (CMRL) -1666. It can be divided into media enriched in various components.
- MEM Minimal essential medium
- RPMI Rosewel Park Memorial Institute
- DMEM Dulbecco's modification of Eagle's medium
- IMDM Iscove's modification of DMEM
- Ham's F-12 Ham's F-12
- CMRL Connaught Medical Research Laboratories
- the growth curve of mammalian cells usually has a Lag phase of 2 to 3 days and the concentration of viable cells decreases rapidly from the end of the delay phase due to the accumulation of ammonium glutamine and lactic acid, a glucose metabolite. .
- Glucose and glutamine are the main carbon and energy sources for mammalian cells.
- glucose is metabolized by mammalian cells, it passes through glycolysis to become pyrubic acid.
- the nucleic acid is synthesized by making a pentose sugar by the pentose phosphate pathway.
- the pyruvic acid produced in glycolysis is decomposed into carbon dioxide and water by the TCA cycle, into lactic acid, and also fatty acid.
- Glutamine is a part of the metabolic process, which becomes glutamate, and glutamate enters the TCA cycle, creating a carbon skeleton for the synthesis of other amino acids.
- Important excreta from mammalian cells are lactic acid and ammonia, and the release of alanine is also important. Lactate and ammonia are toxic to cells because they change the pH of the cells and the lysosomes. As such, since the physiological mechanism and nutritional requirements are different depending on the type of cells cultured, the type of medium used for cell culture should also vary according to characteristics.
- the composition of the medium suitable for the growth conditions of undifferentiated mesenchymal stem cells will be different.
- Patent document 1 mass production method of growth factors using mesenchymal stem cells
- DMEM mesenchymal stem cells
- Ham's F-12 is added to promote differentiation of growth factors from mesenchymal stem cells to significantly increase human growth factors.
- Serum-free medium that is engineered to synthesize is described, but this is based on basic fibroblast growth factor, vascular endothelial growth factor, or mesenchymal stem cell growth from mesenchymal stem cells rather than proliferation of mesenchymal stem cells in basal medium containing DMEM and Ham's F-12. It is for mass production of human transformation growth factor-beta.
- Patent document 2 (medium composition for in vitro proliferation of cord blood-derived mesenchymal stem cells containing soy protein hydrolyzate) is a component of the stem cell culture medium in order to reduce the amount of fetal bovine serum soy protein hydrolyzate to fetal bovine serum It relates to a technique of adding to the low glucose DMEM medium contained.
- Patent document 3 (method of producing dermal papilla tissue using mesenchymal stem cells) and patent document 4 (method of preparing dermal papilla tissue using mesenchymal stem cells) are described in DMEM medium, DMEM / F- 12, F-12, McCoy's 5A, RPMI 1640 medium, William's medium E (Williams' medium E) or IMDMve's Modified Dulbecco's Modification (IMDM) medium, and then cultured as a technique for inducing differentiation into dermal papilla tissue
- the present invention relates to a medium in which hydrocortisone, insulin, insulin, transferrin, and sodium selenite are added to the culture medium.
- Patent document 5 (mesenchymal stem cell culture medium and a method for culturing mesenchymal stem cells using the same) is based on a medium in which a nutrient mixture (Nutrient Mixture) is mixed with a commercially available medium, and additionally, a growth factor of mesenchymal stem cells It is a technology for culturing by adding insulin, hydrocortisone, EGF, LIF, GM-CSF, etc., and is a culture technology for mixing a nutrient mixture in a commercially available culture medium.
- a nutrient mixture Nutrient Mixture
- Patent Document 6 Multipotent Stem Cells Derived from Human Adipose Tissue and Cell Therapeutic Agents Containing It Proliferates mesenchymal stem cells by adding Keratinocyte-SFM medium containing NAC, rEGF, BPE, insulin, etc. based on DMEM medium
- Keratinocyte-SFM medium containing NAC, rEGF, BPE, insulin, etc.
- the basic cell culture medium is DMEM medium.
- Patent Document 7 pharmaceutical prevention or treatment pharmaceutical composition comprising a culture of adult stem cells or fractions thereof
- Patent Document 8 isolated pluripotent adult stem cells and methods for their isolation and culture
- DMEM / Ham's F-12 It is a technique for culturing mesenchymal stem cells using a mixed medium, DMEM medium and DMEM / F-12.
- the conventional techniques are limited to a technique of culturing by adding an additive such as a growth factor based on a commercially available medium.
- Patent Document 9 (cartilage cell specific culture method for early culturing cartilage cells) applied and registered by the present applicant has developed a culture medium in which additives such as growth factors are not added to conventional commercialized media.
- ABSM-C early chondrocyte culture medium
- Patent Document 1 Republic of Korea Patent Registration 10-0899329
- Patent Document 2 Republic of Korea Patent Publication 10-2009-0090850
- Patent Document 3 Republic of Korea Patent Registration 10-1022032
- Patent Document 4 Republic of Korea Patent Publication 10-2010-0110905
- Patent Document 5 Republic of Korea Patent Registration 10-0908481
- Patent Document 6 Republic of Korea Patent Registration 10-0679642
- Patent Document 7 Republic of Korea Patent Publication 10-2009-0121541
- Patent Document 8 Republic of Korea Patent Publication 10-2006-0010847
- Patent Document 9 Republic of Korea Patent Registration 10-1037002
- an object of the present invention is to provide a mesenchymal stem cell basic culture medium capable of proliferating and culturing large numbers of undifferentiated mesenchymal stem cells derived from adult tissues such as human bone marrow and adipose tissue at a rapid growth rate.
- Another object of the present invention is to differentiate the undifferentiated mesenchymal stem cells derived from adult tissues in vitro into osteoblasts, chondrocytes, and adipocytes using mesenchymal stem cell basic culture medium to differentiate into undifferentiated cells.
- mesenchymal stem cell basic culture medium to differentiate into undifferentiated cells.
- An object of the present invention described above is to analyze the types of components of the commercialized culture medium, and then to prepare a variety of candidate base culture medium composition by combining two or more types of culture medium, and intermediate candidate candidate culture medium composition
- Mesenchymal stem cell basics comprising screening the basic culture medium composition suitable for the early culture of mesenchymal stem cells by analyzing the proliferation rate of mesenchymal stem cells in the complete medium containing 10-20% fetal bovine serum of mesenchymal stem cells It is achieved by the culture medium composition method.
- an object of the present invention is a basal medium and DMEM high glucose, RPMI-1640, and Ham's F- mixed with commercially available culture medium DMEM high glucose, RPMI-1640, and Ham's F-12 in a 1: 1: 1 ratio. Comparing each medium of 12, DMEM high glucose medium components as a base component, duplicated components of each medium to select a high concentration, if the component is not included in the DMEM high glucose medium, DMEM high glucose medium, The components contained in only one medium of each medium are maintained at the same concentration. If the ingredients are not included in the DMEM high glucose medium, they are included in the DMEM high glucose medium, and the components of the same source are selected from the components of each medium.
- one of the selected components is a duplicate of each medium, select a high concentration. If the component is not included in the DMEM high glucose medium, it is included in the DMEM high glucose medium and included in ABM-M (Advanced Basic Media). -Mesenchymal stem cell) is achieved by the mesenchymal stem cell basal culture medium prepared.
- the components contained in the DMEM high glucose medium is L-Alanine, L-Asparagine Anhydrous, L-Aspartic acid, L-Glutamic acid, L-Hydroxy in amino acids -L-proline, L-Proline, Inorganic Salts are Cupric Sulfate Pentahydrate, Ferrous Sulfate Heptahydrate, Sodium Phosphate Dibasic Anhydrous, Zinc Sulfate Heptahydrate, and Vitamins (Vitamins) are D-Biotin, P-Aminobenzoic Acid (PABA) ), Vitamine B12, and other components (Hypoxanithine, L-Glutathione Reduced, Linoleic acid, Putrescine + 2HCL, Thioctic Acid, Thymindine).
- PABA P-Aminobenzoic Acid
- the ABM-M medium further includes one or more of fetal, calf, horse or human serum, L-glutamine, antibiotics, and antifungal agents.
- ABM-M medium further comprises 10-20% fetal bovine serum and 2-4mM L-glutamine.
- one component selected from the same source component is L-Arginine Monobydrochloride, L-Asparatic acid, L-Cystine Dibydrochloride, L-Histidine Monobydrochloride Monobydrate in amino acids.
- Inorganic salts are Calcium Chloride Dihydrate, Ferrous Sulfate Heptabydrate, Magnesium Sulfate Anbydrous, Sodium Phosphate Dibasic Anhydrous, and Vitamin (Vitamins) is characterized in that it is Pyridoxal Hydrochloride.
- ABM-M medium expresses at least 80% of CD166, CD105, CD90, CD44, CD29, CD73, HLA-ABC positive surface markers, but CD44, CD105, CD90, CD73 And CD166 positive surface markers are expressed in more than 95%, CD14, CD31, CD34, CD45, CD80 and HLA-DR negative surface markers characterized in that less than 5%.
- ⁇ -MEM fetal bovine serum
- Dexamethasone ß-Glycerophosphate
- Ascorbic acid after culturing the mesenchymal stem cells in ABM-M (Advanced Basic Media-Mesenchymal stem cell) medium
- ABM-M Advanced Basic Media-Mesenchymal stem cell
- an object of the present invention is DMEM low containing Dexamethasone, Ascorbic acid and Sodium pyruvate, TGF- ⁇ , BMP-2 after the mesenchymal stem cells are cultured in ABM-M (Advanced Basic Media-Mesenchymal stem cell) medium It is achieved by a cell therapy for osteoarthritis treatment, characterized in that the culture medium is differentiated again in glucose medium to differentiate into chondrocytes.
- ABM-M Advanced Basic Media-Mesenchymal stem cell
- an object of the present invention is cultured in the ⁇ -MEM medium containing fetal bovine serum, Ddexamethasone, Indomethacin, Insulin after culturing mesenchymal stem cells in ABM-M (Advanced Basic Media-Mesenchymal stem cell) medium It is achieved by a cell therapy for adipocytes, characterized in that the differentiation into adipocytes.
- mesenchymal stem cell basic culture medium of the present invention it is possible to mass-proliferate and culture the undifferentiated mesenchymal stem cells, which are human adult stem cells, at a rapid growth rate, and to maintain the cell karyotype even after prolonged culture growth for 1 month or more. It can be used as a cell therapy by differentiating into derivatives of bone forming cells, chondrocytes, and adipocytes.
- 1 is a medium containing bone marrow-derived mesenchymal stem cells containing an additive and 10% fetal bovine serum in MSC-BM as a control group, and a medium containing an additive and 10% fetal bovine serum in ABM-M medium of the present invention. Inoculated at a concentration of 375,000 cells in a T75 flask incubated for 10 days, a graph showing the growth of mesenchymal stem cells.
- Figure 3 is bone marrow-derived mesenchymal stem cells were grown in a medium containing the additive and 10% fetal calf serum in MSC-BM control group and the medium containing the additive and 10% fetal calf serum in ABM-M medium of the present invention Graph showing the proliferation rate of mesenchymal stem cells.
- Figure 4 is a graph showing the passage-specific proliferation of mesenchymal stem cells propagated in adipose derived mesenchymal stem cells control medium containing ADSCGM and 10% fetal bovine serum in ABM-M medium of the present invention.
- Figure 5 is bone marrow or fat-derived mesenchymal stem cells cultured in the control group MSCGM medium or ADSCGM medium and bone marrow or fat cultured in a culture medium containing 10% fetal bovine serum and 2mM L-glutamine in ABM-M of the present invention
- SS derived mesenchymal stem cells
- Figure 6 is a graph showing the histogram for the immunological cellular characteristics analysis of bone marrow-derived mesenchymal stem cells cultured in a medium containing 10% fetal bovine serum and 2mM L-glutamine in ABM-M medium of the present invention.
- Figure 7 is a graph showing the histogram for the analysis of immunological cellular characteristics of adipose derived mesenchymal stem cells cultured in a medium containing 10% fetal bovine serum and 2mM L-glutamine in ABM-M medium of the present invention.
- ABM-M medium 8 is a culture medium for bone marrow cell differentiation after culturing bone marrow and fat-derived mesenchymal stem cells cultured in a medium containing 10% fetal bovine serum and 2 mM L-glutamine in ABM-M medium of the present invention (10 ALPase and von Kossa staining after 2-3 weeks of differentiation and differentiation in ⁇ -MEM medium containing fetal calf serum, 10 mM ⁇ -glycerol phosphate, 50 uM ascorbic acid and 10 -7 M dexamethasone.
- Figure 9 after culturing the bone marrow and fat-derived mesenchymal stem cells cultured in a medium containing 10% fetal bovine serum and 2mM L-glutamine in ABM-M medium of the present invention, adipocyte differentiation medium (10% right Oil Red-O staining after two weeks of culture differentiation in fetal serum, ⁇ -MEM medium containing 10 -7 M dexamethasone, 100 uM indomethacin and 10 ug / mL insulin.
- adipocyte differentiation medium (10% right Oil Red-O staining after two weeks of culture differentiation in fetal serum
- ⁇ -MEM medium containing 10 -7 M dexamethasone 100 uM indomethacin and 10 ug / mL insulin.
- Figure 10 after culturing bone marrow-derived mesenchymal stem cells cultured in a medium containing 10% fetal bovine serum and 2mM L-glutamine in ABM-M medium of the present invention, to induce differentiation into chondrocytes 5 10 5 Cells were centrifuged at 300 g for 5 minutes to form cell masses, followed by DMEM high glucose medium containing 10 -7 M dexamethasone, 50 uM ascorbic acid, 1 nM sodium pyruvate, 10 ng / mL TGF- ⁇ and 100 ng / mL BMP-2.
- FIG. 11 is a photograph showing analysis of karyotype after 10 passages of bone marrow-derived mesenchymal stem cells cultured in a medium containing 10% fetal bovine serum and 2 mM L-glutamine in ABM-M medium of the present invention.
- FIG. 12 is a photograph showing analysis of karyotype after 10 passages of adipose derived mesenchymal stem cells cultured in a medium containing 10% fetal bovine serum and 2 mM L-glutamine in ABM-M medium of the present invention.
- Figure 13 is a picture of morphological abnormality and adhesion loss of mesenchymal stem cells during cell culture of mesenchymal stem cells in conventional ABM-C medium.
- the present invention provides a mesenchymal stem cell basic culture medium derived from adult tissues such as bone marrow and adipose, and the mesenchymal stem cell basic culture medium of the present invention is analyzed after analyzing the kinds of components of the commercialized medium, Combining the above medium to prepare a variety of candidate basal culture medium composition, and the mesenchymal stem cells to the candidate basal culture medium composition for the growth rate of mesenchymal stem cells in the complete medium containing 10-20% fetal bovine serum Analyzing and screening a suitable basal culture medium composition of mesenchymal stem cells.
- mesenchymal stem cell basic culture medium of the present invention prepared as described above, it is analyzed whether the mesenchymal stem cells cultured early at a rapid growth rate show immunological cellular characteristics, and then into osteoblasts, chondrocytes, and adipocytes. Analyze differentiation or differentiation capacity, and analyze cell nuclei to determine whether they can be cultured for a long period of time without mutations due to chromosomal abnormalities, to treat bone loss, to treat osteoarthritis, and to treat adipocytes through adipose tissue formation It can be used as a cell therapy product.
- the mesenchymal stem cell basic culture medium of the present invention in order to verify whether the mesenchymal stem cell basic culture medium of the present invention can be used as a cell therapy, it is necessary to analyze immunological cell characteristics, differentiation capacity, and cell karyotype. desirable. First, analyzing the immunological cell characteristics of mesenchymal stem cells cultured with the screened medium composition; Analyzing the differentiation capacity of the mesenchymal stem cells cultured with the screened medium composition; And to verify the long-term culture of the mesenchymal stem cells cultured with the screened medium composition to verify the cell karyotype.
- ABM-M (Advanced Basic Media-Mesenchymal stem cell) medium of the mesenchymal stem cell basic culture medium of the present invention is a 1: 1: 1 ratio of DMEM high glucose, RPMI-1640, and Ham's F-12, which are commercially available culture media.
- the basal medium mixed with DMEM high glucose medium was prepared, and the basal medium was compared with the medium of DMEM high glucose, RPMI-1640, and Ham's F-12 with DMEM high glucose medium as the base component.
- the concentration is selected, if it is not included in the DMEM high glucose medium, it is included in the DMEM high glucose medium (Remarks 1 in Table 1), and the components contained in only one medium of each medium are maintained in the same concentration, and the DMEM high glucose medium is If the components are not included in the medium, DMEM high glucose medium (remarks 2 in Table 1), the components of each medium are the same source of the components of the selected one of the components of each medium is duplicated component If select a high concentration, high glucose DMEM medium supplemented with the ingredients is not included in DMEM high glucose medium (remarks of Table 1 3) to be the composition as shown in Table 1 below.
- the components included in the DMEM high glucose medium which is a basic component of the ABM-M medium of the present invention is included in the amino acid (Amino Acids) L-Alanine, L-Asparagine Anhydrous, L-Aspartic acid, L-Glutamic acid, L-Hydroxy-L-proline, L-Proline, and Inorganic Salts, Cupric Sulfate Pentahydrate, Ferrous Sulfate Heptahydrate, Sodium Phosphate Dibasic Anhydrous, Zinc Sulfate Heptahydrate, Vitamins) are D-Biotin, P-Aminobenzoic Acid (PABA), Vitamine B12, and other components are Hypoxanithine, L-Glutathione Reduced, Linoleic acid, Putrescine + 2HCL, Thioctic Acid, Thymindine.
- amino acid Amino Acids
- PABA P-Aminobenzoic Acid
- Vitamine B12 and other components are Hypox
- ABM-M Advanced Basic Media-Mesenchymal stem cell
- the duplicated component selects a high concentration. If the component is not included in the DMEM high glucose medium, it is included in the remarks column 1 of Table 1 in the DMEM high glucose medium.
- amino acids Glycine, L-Glutamine, L-Isoleucine, L-Leucine, L-Lysine, L-Methionine, L-Phenylalaine, L-Serine, L-Threonine, L-Tryptophan, L-Tyrosine, L-Valine By selecting the higher concentrations of the major amino acids in the protein enhanced protein synthesis and increased cell proliferation.
- Inorganic salts Patassium Chloride and Sodium Chloride are related to the intracellular and external osmotic pressures, and the higher components were selected to maintain the proper osmotic pressure.
- Vitamins Ascorbic Acid Phosphate, Choline Chloride, D-Biotin (in DMEM high glucose medium), D-Ca Pantothenate, Folic Acid, Myo-Inositol, Nicotinamide, Riboflavin, Thiamine Hydrochloride, Vitamine B12 (in DMEM high glucose medium) was selected as a high concentration to remove the waste produced by the high proliferation of cells with antioxidants.
- the other component, D-Glucose Anhydrous was chosen as the main energy source and the high concentration was chosen as the energy source to maintain high proliferation.
- Phenol Red Sodium Salt is not related to cell proliferation, but it is a waste product discharged by active cell proliferation, which changes the color of Phenol Red from red to yellow. High concentrations were selected for measurement.
- Proline is a major component of collagen and a major component of extracellular matrix synthesis. In order to increase the synthesis of collagen in mesenchymal stem cells of high proliferation was included in DMEM high glucose medium.
- Aspartic acid is found in most proteins and is linked to the citric acid cycle to provide amino groups for purine bases and pyrimidine bases. Therefore, the main sources of DNA synthesis of cells with high proliferation rate were included in DMEM high glucose medium as the main source of purine and pyrimidine bases.
- L-Glutamic acid is an important amino acid of cellular metabolism and was included in DMEM high glucose medium for the active growth of cells.
- ABM-C medium composed of DMEM and RPMI-1640 to increase the proliferation rate, cell adhesion was lost.
- the components of DMEM high glucose medium were included to increase the synthesis of collagen and to remove the waste caused by the increased synthesis.
- L-Alanine an amino acid involved in cell immunity and synthesis, is included to enhance the proliferation of mesenchymal stem cells, and the amino acid L-Hydroxy-L-Proline, other components Thioctic Acid and Linoleic Acid, and vitamin P -Aminobenzoic Acid (PABA) is a component of intracellular collagen and was included in DMEM high glucose medium to enhance cell adhesion by increasing the synthesis of intracellular collagen.
- Inorganic salts Cupric Sulfate Penatahydrate and Zinc Sulfate Heptahydrate, and other ingredients, Glutathione Reduced, were included in DMEM high glucose medium to show high cell proliferation rate by further enhancing the release of various apoptosis cells with high proliferation rate as antioxidants.
- Thymidine Thymidine
- Putrescine + 2HCL Hypoxanthine
- components that are the same source are selected by selecting one component and selecting a high concentration if one selected component is a duplicate of each medium, and DMEM high glucose if the component is not included in the DMEM high glucose medium. Inclusion in the medium corresponds to the remarks column 3 in Table 1.
- L-Arginine L-Asparagine, L-Cysteine / cystine, L-Histidine, Minerals Calcium Chloride / Nitrate, Ferric Nitrage / Ferrous Sulfate, Sodium Phosphate, Vitamins Pyridoxal Hydrochloride / Pyridoxine Hydrochloride
- the addition of two or more components may increase the osmotic pressure in the medium may adversely affect the cells, so the same components were selected at a single concentration by selecting a high concentration of components.
- Sodium phosphate was selected as 142.04 mg / L in order to maintain an appropriate osmotic pressure because an exceptionally high concentration could increase the total osmotic pressure of the medium, which could adversely affect the cells.
- Magnesium Chloride Hexahydrate and Magnesium Sulfate Anhydrous are the source of Magnesium, which is the major substance for intracellular metabolism, and anhydrous Magnesium Sulfate Anhydrous was selected to reduce salt formation in the medium preparation.
- L-Asparatic acid (20 mg / L) among L-Asparagine Monobydrate and L-Asparatic acid
- L-Cystine Dibydrochloride (62.6 mg / L) among L-Cysteine Monobydrochloride Monobydrate and L-Cystine Dibydrochloride
- L-Histidine Monobydrochloride Monobydrate (42 mg / L) is selected from L-Histidine and L-Histidine Monobydrochloride Monobydrate.
- Calcium Chloride Dihydrate (265 mg / L) is selected from Calcium Chloride Dihydrate and Calcium Nitrate Tetrahydrate
- Ferrous Sulfate Heptabydrate (0.834 mg / L) is selected from Ferric Nitrate Nonabydrate and Ferrous Sulfate Heptabydrate
- Magnesium Sulfate Anbydrous (97.67 mg / L) is selected from Magnesium Chloride Hexabydrate and Magnesium Sulfate Anbydrous
- Sodium Phosphate Dibasic Anhydrous (142.04 mg / L) is selected from Sodium Phosphate Dibasic Anhydrous and Sodium Phosphate Monobasic Anhydrous.
- Pyridoxal Hydrochloride (4 mg / L) is selected from Pyridoxal Hydrochloride and Pyridoxine Hydrochloride.
- the composition of the Advanced Basic Media-Mesenchymal Stem Cell (ABM-M) for culturing mesenchymal stem cells derived from adult tissues such as bone marrow and fat in vitro is DMEM high.
- DMEM Advanced Basic Media-Mesenchymal Stem Cell
- the composition is based on the components of DMEM high glucose.
- the ABM-M medium of the present invention is mesenchymal stem cells are classified as adult stem cells in which the proliferation and synthesis of cells are not active, and the DMEM high glucose medium has a high concentration of amino acid DMEM high It is a medium that adjusts the concentration of constituents such as amino acids, inorganic salts and vitamins that are absent or low in glucose medium.
- Mesenchymal stem cells refer to undifferentiated cells having multipotency derived from adult tissues of mammals including humans.
- Adult tissues include bone marrow, blood, brain, skin, fat, umbilical cord blood and the like.
- Mesenchymal stem cells can be separated from adult tissues such as bone marrow or adipose tissue through various methods. For example, separation method by density purchase centrifugation such as Percoll (Majumdar MK et al ., J. Cell Physiol . 176: 57, 1998; Majka SM et al ., J. Clin. Invest ., 111: 71, 2003) or by enzymatic treatment such as collagenase (collagnease) to separate the cells growing on the bottom of the culture vessel by the method of Luria et al . (Luria et al ., Transfusion, 11: 345, 1971). It can be separated easily by the separation method.
- density purchase centrifugation such as Percoll (Majumdar MK et al ., J. Cell Physiol . 176: 57, 1998; Majka SM et al ., J. Clin. Invest ., 111: 71, 2003) or
- the mesenchymal stem cell basic culture medium of the present invention is for culturing mesenchymal stem cells isolated from adult bone marrow, blood, brain, skin, fat, umbilical cord blood, etc., and may add one or more components as necessary.
- Antibiotics and antifungal agents for the prevention of microbial contamination including fetal calf, horse or human serum and L-glutamine, can be used.
- the mesenchymal stem cells are cultured in the basal culture medium of the present invention.
- CD166, CD105, CD90, CD44, CD29, CD73, HLA-ABC positive surface markers express more than 80%, in particular CD44, CD105, CD90, CD73 and CD166 positive surface markers express at least 95%, and CD31, CD34, CD45, CD80 and HLA-DR negative surface markers exhibit immunological cellular characteristics of up to 5%.
- the spindle exhibits the morphological characteristics of the spindle (shape) to attach to the plastic culture vessel to proliferate, and to show the characteristics of differentiating ability to proliferate in a dichotomous state.
- the cultured mesenchymal stem cells were confirmed to be multipotent mesenchymal stem cells capable of differentiation into osteoblasts, chondrocytes and adipocytes.
- the present invention is also cultured in mesenchymal stem cells in ABM-M (Advanced Basic Media-Mesenchymal stem cell) medium and then incubated again in ⁇ -MEM medium containing fetal bovine serum, Dexamethasone, ß-Glycerophosphate, Ascorbic acid to provide a cell therapy for the treatment of bone deletion containing mesenchymal stem cells capable of differentiating into bone forming cells.
- ABM-M Advanced Basic Media-Mesenchymal stem cell
- the present invention also provides a DMEM low glucose medium comprising Dexamethasone, Ascorbic acid, Sodium pyruvate, TGF- ⁇ , BMP-2 after mesenchymal stem cells are cultured in ABM-M (Advanced Basic Media-Mesenchymal stem cell) medium. It provides a cell therapy for osteoarthritis treatment containing mesenchymal stem cells that can be cultured again to differentiate into chondrocytes.
- ABM-M Advanced Basic Media-Mesenchymal stem cell
- the mesenchymal stem cells are cultured in ABM-M (Advanced Basic Media-Mesenchymal stem cell) medium and then cultured again in ⁇ -MEM medium containing fetal bovine serum, Ddexamethasone, Indomethacin, and Insulin to adipocytes. It provides a cell therapy for forming adipose tissue containing mesenchymal stem cells capable of differentiation.
- ABM-M Advanced Basic Media-Mesenchymal stem cell
- mesenchymal stem cell basic culture medium of the present invention Advanced Basic Media-Mesenchymal stem cell, ABM-M
- ABM-M Advanced Basic Media-Mesenchymal stem cell
- ABSM-M mesenchymal stem cell basal culture medium
- bone marrow-derived mesenchymal stem cells and adipose derived mesenchymal stem cells frozen from Lonza were prepared.
- Bone marrow-derived mesenchymal stem cells were purchased and cultured in Poietics MSCGM TM Bullekit, and adipose-derived mesenchymal stem cells were compared with cultured media in Poietics ADSC-GM TM Bullekit.
- Mesenchymal stem cells derived from bone marrow purchased from Lonza were quickly thawed in a 37 ° C. hot water bath, and then placed in a 15 mL tube containing 5 mL of MSCGM TM medium and centrifuged at 300 g for 5 minutes. After centrifugation, the supernatant medium was removed and suspended in 10 mL of fresh MSCGM medium to determine cell number and cell viability.
- Prepared cells were inoculated with 5,000 cells per cm 2 in a T25 flask and maintained at 37 ° C. and 5% CO 2 . Every 3-4 days, the culture medium was exchanged with 5 mL of MSCGM medium for each culture vessel. Subcultures were performed if cells grew more than 90% of the flask bottom area. Second, third and fourth cultures were used to prepare the test cell numbers.
- Mesenchymal stem cells derived from adipose tissue purchased from Lonza were quickly thawed in a 37 ° C. hot water bath, and then placed in a 15 mL tube with 5 mL of ADSC-GM medium and centrifuged at 300 g for 5 minutes. After centrifugation, the supernatant medium was removed and suspended in 10 mL of fresh ADSC-GM medium to determine cell number and cell viability.
- Prepared cells were inoculated with 5,000 cells per cm 2 in a T25 flask and maintained at 37 ° C. and 5% CO 2 . Every 3-4 days, the culture medium was exchanged with 5 mL of ADSC-GM medium containing 10% fetal bovine serum for each culture vessel. Subcultures were performed if cells grew more than 90% of the flask bottom area. Secondary, third and fourth passages were used to prepare test cell numbers.
- MSCGM medium is composed of MSC-BM base medium and additives (consisting of 50 mL growth supplement, 10 mL L-glutamine, 0.5 mL penicillin-streptomy), and the additives were also added to the ABM-M medium (Table 2). ).
- Proliferative medium composition of ABM-M medium and MSCGM medium of the present invention is provided.
- the medium (MSC-BM + FBS) added with 10% fetal bovine serum (FBS) to MSC-BM did not grow for 10 days and the additive added MSC- BM MSCGM medium also showed little growth.
- the growth of the medium (ABM-M + FBS) to which the 10% fetal bovine serum (FBS) was added to the ABM-M medium of the test group was higher than that of MSCGM and the doubling time was also faster.
- the medium containing the additive in the ABM-M also showed higher proliferation and faster doubling time than the MSCGM, confirming that the ABM-M medium composition increased the proliferation rate of mesenchymal stem cells derived from bone marrow.
- Bone marrow-derived mesenchymal stem cells were not grown in MSCGM medium, while bone marrow-derived mesenchymal stem cells were grown in ABM-M medium containing 10% fetal bovine serum and 2 mM L-glutamine. This shows that the proliferative capacity of mesenchymal stem cells cultured in MSCGM medium was lost, but the proliferative capacity was maintained in ABM-M medium.
- ABM-M medium In order to confirm the sustained proliferative capacity in ABM-M medium, cells recovered in the fifth passage were inoculated with 5,000 cells per cm 2 in a T150 flask and maintained at 37 ° C. and 5% CO 2 . Every 3-4 days, culture medium was exchanged with ABM-M medium containing 10% fetal bovine serum and 2mM L-glutamine every 3-4 days, and after culturing for 10 days, the number of cells was recovered, and 3,357,500 cells were recovered and inoculated. It was confirmed that the proliferative capacity was maintained by showing 447% growth rate compared to the cell number 750,000. Therefore, the ABM-M medium of the present invention was confirmed that the proliferation ability of bone marrow-derived mesenchymal stem cells.
- ADSC-GM medium is composed of ADSCC-BM basal medium and additives (consisting of 50 mL fetal bovine serum, 5 mL L-glutamine, 0.5 mL gentamicin-amphotercin), so that 10% fetal bovine serum in ABM-M medium of the present invention And 2mM L-glutamine was added to perform a comparative test.
- 5,000 cells per cm 2 were inoculated into T75 flasks containing each medium and maintained at 37 ° C. and 5% CO 2 . After culturing for 7 days while replacing the culture medium with each medium for each culture vessel every 3-4 days, the cell number was measured. In addition, the recovered cells were passaged and inoculated with 5,000 cells per cm 2 in a T175 flask containing medium to maintain 37 ° C. and 5% CO 2 . After culturing for 7 days while replacing the culture medium with each medium for each culture vessel every 3-4 days, the cell number was measured.
- the medium (ABM-M + FBS) added with 10% fetal bovine serum to ABM-M medium of the present invention which is a test group, than the control group ADSC-GM, 5th and 6th passages It showed a fast doubling time in culture and recovered a lot of cells was confirmed that the proliferation rate of fat-derived mesenchymal stem cells by the ABM-M medium of the present invention (Table 4).
- Cells cultured in the culture medium of 1-2 and 1-3 of Example 1 were removed by treatment with TrypLE express, centrifuged at 400 g for 5 minutes to obtain cells, and then washed twice with FASC solution and washed. Dissociate 5 10 5 cells for 20 minutes with anti-CD166, CD105, CD90, CD44, CD29, CD73, HLA-ABC, CD31, CD34, CD45, CD80 and HLA-DR antibodies, and then wash and FACS solution was suspended and analyzed using a flow cytometer. The surface of the cells was analyzed to determine the phenotype of mesenchymal stem cells.
- adipocytes Differentiation into adipocytes is shown in Figure 9, the mesenchymal stem cells pre-cultured in ABM-M medium containing 10% fetal bovine serum, 10 -7 M dexamethasone, 100uM indomethacin and 10ug / mL insulin After two weeks of culture differentiation in MEM medium, it was confirmed by staining fat droplets accumulated in cells by oil Red-O staining.
- Differentiation-induced cartilage tissue was made through paraffin embedding to prepare 5um serial sections, and differentiated into cartilage tissue through H / E staining, safranin O staining, alcian blue staining, sirius red staining, COMP staining, collagen type II and I staining. It was confirmed.
- Bone marrow and adipose-derived mesenchymal stem cells cultured in the ABM-M medium of the present invention were compared with a control group that did not induce multiple differentiation after two passages.
- ALP staining and calcium infiltration induced by osteoblasts alkaline phaphatase expression and calcium deposition were confirmed, unlike the control group that did not induce differentiation.
- oil Red-O staining by adipocytes it was confirmed that differentiation into adipocytes, unlike the control group did not induce differentiation.
- glycosaminoglycan GAG
- proteoglycan collagen type similar to normal cartilage through safranin O staining, alcian blue staining, sirius red staining, COMP staining, collagen type II and I staining Expression of I was confirmed.
- ABM- containing 10% fetal bovine serum and 2 mM L-glutamine by separating mesenchymal stem cells from adult tissues such as bone marrow and adipose tissue derived from different individuals, such as 1-2 and 1-3 of Example 1
- the karyotypes of cultured mesenchymal stem cells were analyzed. Five of the fission metaphase phases were analyzed using GTG desalination, and karyotypes were designated according to the International System for Cytogenetic Nomenclature (2009). 11 shows normal 46 and XY karyotypes, and FIG. 12 shows normal 46 and XX karyotypes in all five mitotic cells observed.
- the mesenchymal stem cell basic culture medium (ABM-M medium) of the present invention maintains the cellular characteristics and differentiation capacity of mesenchymal stem cells as compared to the conventional mesenchymal stem cell culture medium, and also promotes cell growth and proliferation.
- This excellent medium can be used to culture mesenchymal stem cells in large quantities to obtain pure mesenchymal stem cells.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Developmental Biology & Embryology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (10)
- 상용화된 배양 배지의 구성성분의 종류를 분석한 후, 2종류 이상의 배양 배지를 조합하여 여러 종류의 후보 기본 배양 배지 조성을 준비하는 단계와,후보 기본 배양 배지 조성을 대상으로 중간엽 줄기세포를 10~20% 우태아 혈청이 포함된 완전 배지에서 중간엽 줄기세포의 증식률을 분석하여 중간엽 줄기세포의 조기 배양에 적합한 기본 배양 배지 조성을 스크린 하는 단계를 포함하는 중간엽 줄기세포 기본 배양 배지 조성방법.
- 상용화된 배양 배지인 DMEM high glucose, RPMI-1640, 및 Ham's F-12를 1:1:1 비율로 혼합한 기본 배지와 DMEM high glucose, RPMI-1640, 및 Ham's F-12의 각 배지를 비교하되,DMEM high glucose 배지 성분을 기본성분으로 하여각 배지 중에서 중복된 성분은 높은 농도를 선택하는데, DMEM high glucose 배지에 포함되지 않은 성분이면 DMEM high glucose 배지에 포함하며,각 배지 중 하나의 배지에만 들어 있는 성분들은 농도 그대로를 유지하는데, DMEM high glucose 배지에 포함되지 않은 성분이면 DMEM high glucose 배지에 포함하며,각 배지의 성분 중에서 동일 공급원인 성분들은 하나의 성분을 선택하여 선택한 하나의 성분이 각 배지의 중복된 성분이면 높은 농도를 선택하는데, DMEM high glucose 배지에 포함되지 않은 성분이면 DMEM high glucose 배지에 포함하여 ABM-M(Advanced Basic Media-Mesenchymal stem cell) 배지를 조성한 것을 특징으로 하는 중간엽 줄기세포 기본 배양 배지.
- 청구항 2에 있어서,DMEM high glucose 배지에 포함되는 성분은아미노산(Amino Acids)에서는 L-Alanine, L-Asparagine Anhydrous, L-Aspartic acid, L-Glutamic acid, L-Hydroxy-L-proline, L-Proline이고,무기염(Inorganic Salts)에서는 Cupric Sulfate Pentahydrate, Ferrous Sulfate Heptahydrate, Sodium Phosphate Dibasic Anhydrous, Zinc Sulfate Heptahydrate이고,비타민(Vitamins)에서는 D-Biotin, P-Aminobenzoic Acid(PABA), Vitamine B12이고,기타 성분(Other components)에서는 Hypoxanithine, L-Glutathione Reduced, Linoleic acid, Putrescine+2HCL, Thioctic Acid, Thymindine인 것을 특징으로 하는 중간엽 줄기세포 기본 배양 배지.
- 청구항 2에 있어서,ABM-M 배지에는 태아, 송아지, 말 또는 사람의 혈청, L-glutamine, 항생제, 및 항진균제 중에서 하나 이상을 더 포함하는 중간엽 줄기세포 기본 배양 배지.
- 청구항 2에 있어서,ABM-M 배지에는 10-20% 우태아혈청과 2-4mM의 L-glutamine을 더 포함하는 중간엽 줄기세포 기본 배양 배지.
- 청구항 2에 있어서,동일 공급원인 성분에서 선택되는 하나의 성분은아미노산(Amino Acids)에서는 L-Arginine Monobydrochloride, L-Asparatic acid, L-Cystine Dibydrochloride, L-Histidine Monobydrochloride Monobydrate 이고,무기염(Inorganic Salts)에서는 Calcium Chloride Dihydrate, Ferrous Sulfate Heptabydrate, Magnesium Sulfate Anbydrous, Sodium Phosphate Dibasic Anhydrous 이며,비타민(Vitamins)에서는 Pyridoxal Hydrochloride인 것을 특징으로 하는 중간엽 줄기세포 기본 배양 배지.
- 청구항 2에 있어서,ABM-M 배지는 CD166, CD105, CD90, CD44, CD29, CD73, HLA-ABC 양성 표면 마커를 80% 이상 발현하되, CD44, CD105, CD90, CD73와 CD166 양성 표면 마커는 95% 이상 발현하고, CD14, CD31, CD34, CD45, CD80와 HLA-DR 음성 표면 마커를 5%이하 발현하는 것을 특징으로 하는 중간엽 줄기세포 기본 배양 배지.
- 청구항 2의 ABM-M(Advanced Basic Media-Mesenchymal stem cell) 배지에서 중간엽 줄기세포가 배양된 다음에 우태아혈청, Dexamethasone, ß-Glycerophosphate, Ascorbic acid를 포함하는 α-MEM 배지에서 다시 배양분화되어 골 형성세포로 분화되는 것을 특징으로 하는 골 결실 치료용 세포치료제.
- 청구항 2의 ABM-M(Advanced Basic Media-Mesenchymal stem cell) 배지에서 중간엽 줄기세포가 배양된 다음에 Dexamethasone, Ascorbic acid와 Sodium pyruvate, TGF-β, BMP-2를 포함하는 DMEM low glucose 배지에서 다시 배양분화되어 연골세포로 분화되는 것을 특징으로 하는 골관절염 치료용 세포치료제.
- 청구항 2의 ABM-M(Advanced Basic Media-Mesenchymal stem cell) 배지에서 중간엽 줄기세포가 배양된 다음에 우태아혈청, Ddexamethasone, Indomethacin, Insulin을 포함하는 α-MEM 배지에서 다시 배양분화되어 지방세포로 분화되는 것을 특징으로 하는 지방조직 형성용 세포치료제.
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201180073169.4A CN103857789B (zh) | 2011-08-31 | 2011-09-06 | 制备间充质干细胞基础培养基和利用间充质干细胞基础培养基制备细胞治疗产品的方法及用该培养基得到的分化产品 |
ES11871607.5T ES2660898T3 (es) | 2011-08-31 | 2011-09-06 | Método para preparar un medio de cultivo básico para células madre mesenquimatosas, medio de cultivo básico para células madre mesenquimatosas, y agente terapéutico celular cultivado y diferenciado usando el mismo |
NO11871607A NO2752484T3 (ko) | 2011-08-31 | 2011-09-06 | |
DK11871607.5T DK2752484T3 (en) | 2011-08-31 | 2011-09-06 | PROCEDURE FOR PREPARING A BASIC CULTURAL MEDIUM FOR MESENKYMAL STEM CELLS, BASIC CULTURAL MEDIUM FOR MESENKYMAL STEM CELLS, AND CELL THERAPEUTIC AGENTS CULTIVATED AND DIFFERENTIALLY USED |
PL11871607T PL2752484T3 (pl) | 2011-08-31 | 2011-09-06 | Sposób wytwarzania podstawowej pożywki hodowlanej dla mezenchymalnych komórek macierzystych, podstawowa pożywka hodowlana dla mezenchymalnych komórek macierzystych i komórkowy środek terapeutyczny hodowany i różnicowany z jej użyciem |
EP11871607.5A EP2752484B1 (en) | 2011-08-31 | 2011-09-06 | Method for preparing a basic culture medium for mesenchymal stem cells, basic culture medium for mesenchymal stem cells, and cell therapeutic agent cultured and differentiated using same |
JP2014528250A JP5872046B2 (ja) | 2011-08-31 | 2011-09-06 | 間葉系幹細胞の基本培養培地の調製方法 |
LTEP11871607.5T LT2752484T (lt) | 2011-08-31 | 2011-09-06 | Bazinė mitybinė terpė mezenchiminėms kamieninėms ląstelėms, bazinės mitybinėms terpės mezenchiminėms kamieninėms ląstelėms gamybos būdas ir ląstelės terapinis agentas, kultivuojamas ir diferencijuojamas panaudojant šį būdą |
SI201131429T SI2752484T1 (en) | 2011-08-31 | 2011-09-06 | A method for preparing a basic medium for mesenchymal stem cells, a basic medium for mesenchymal stem cells and a cell therapeutic agent, cultured and differentiated using it |
US14/241,393 US9879226B2 (en) | 2011-08-31 | 2011-09-06 | Mesenchymal stem cell basic culturing medium |
HRP20180266TT HRP20180266T1 (hr) | 2011-08-31 | 2018-02-13 | Postupak priprave osnovnog medija za kulturu mezenhimnih matičnih stanica, osnovni medij za kulturu mezenhimnih matičnih stanica, te terapijsko sredstvo za stanice koje se uzgaja i diferencira uz njegovu upotrebu |
CY20181100198T CY1119924T1 (el) | 2011-08-31 | 2018-02-21 | Μεθοδος για παρασκευη ενος βασικου μεσου καλλιεργειας για μεσεγχυματικα βλαστοκυτταρα, βασικο μεσο καλλιεργειας για μεσεγχυματικα βλαστοκυτταρα, και κυτταρικος θεραπευτικος παραγοντας καλλιεργημενος και διαφοροποιημενος με χρηση αυτου |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2011-0087498 | 2011-08-31 | ||
KR1020110087498A KR101138091B1 (ko) | 2011-08-31 | 2011-08-31 | 중간엽 줄기세포 기본 배양 배지 조성방법, 중간엽 줄기세포 기본 배양 배지 및 이를 이용하여 배양분화된 세포치료제 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013032052A1 true WO2013032052A1 (ko) | 2013-03-07 |
Family
ID=46143924
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2011/006582 WO2013032052A1 (ko) | 2011-08-31 | 2011-09-06 | 중간엽 줄기세포 기본 배양 배지 조성방법, 중간엽 줄기세포 기본 배양 배지 및 이를 이용하여 배양분화된 세포치료제 |
Country Status (17)
Country | Link |
---|---|
US (1) | US9879226B2 (ko) |
EP (1) | EP2752484B1 (ko) |
JP (1) | JP5872046B2 (ko) |
KR (1) | KR101138091B1 (ko) |
CN (1) | CN103857789B (ko) |
CY (1) | CY1119924T1 (ko) |
DK (1) | DK2752484T3 (ko) |
ES (1) | ES2660898T3 (ko) |
HR (1) | HRP20180266T1 (ko) |
HU (1) | HUE036910T2 (ko) |
LT (1) | LT2752484T (ko) |
NO (1) | NO2752484T3 (ko) |
PL (1) | PL2752484T3 (ko) |
PT (1) | PT2752484T (ko) |
SI (1) | SI2752484T1 (ko) |
TR (1) | TR201802355T4 (ko) |
WO (1) | WO2013032052A1 (ko) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016027850A1 (ja) * | 2014-08-21 | 2016-02-25 | 味の素株式会社 | 間葉系幹細胞用培地 |
USD848022S1 (en) | 2017-07-14 | 2019-05-07 | Hope Biosciences, Llc | Container for storing biological material |
USD875967S1 (en) | 2017-07-14 | 2020-02-18 | Hope Biosciences, Llc | Container for storing biological material |
US10894947B1 (en) | 2016-04-29 | 2021-01-19 | Hope Biosciences, Llc | Method for generating protein rich conditioned medium |
US10959425B2 (en) | 2016-04-29 | 2021-03-30 | Hope Biosciences, Llc | Method of banking stem cells |
US10988731B2 (en) | 2016-04-29 | 2021-04-27 | Hope Biosciences, Llc | Formulation for storage, transportation, and delivery of protein rich conditioned medium |
US11111480B2 (en) | 2016-04-29 | 2021-09-07 | Hope Biosctences, Llc | Culture media for multipotent stem cells |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6600299B2 (ja) | 2013-05-10 | 2019-10-30 | ザ チルドレンズ メディカル センター コーポレーション | 創傷治癒および組織工学 |
KR101548956B1 (ko) | 2013-09-05 | 2015-09-01 | 메디포스트(주) | 세포 크기에 따른 간엽줄기세포 배양방법 |
CN104877962A (zh) * | 2015-04-15 | 2015-09-02 | 广州赛莱拉干细胞科技股份有限公司 | 一种无血清的脂肪干细胞培养基及其制备方法 |
CN104877961A (zh) * | 2015-04-15 | 2015-09-02 | 广州赛莱拉干细胞科技股份有限公司 | 一种无血清的人羊膜间充质干细胞培养基及其制备方法 |
EP3090764A1 (en) * | 2015-05-08 | 2016-11-09 | Université Catholique De Louvain | Compositions comprising mesenchymal stem cells and uses thereof |
CN105039247B (zh) * | 2015-07-13 | 2018-07-20 | 暨南大学 | 一种用于诱导干细胞向成软骨分化的制剂及制备方法与应用 |
KR20180012223A (ko) * | 2016-07-25 | 2018-02-05 | 고려대학교 산학협력단 | 자궁 유래 성체줄기세포 분리 및 제조 방법 |
CN106520687B (zh) * | 2016-10-12 | 2019-12-27 | 广东艾时代生物科技有限责任公司 | 一种诱导多能干细胞向间充质干细胞分化的方法 |
CN106635975A (zh) * | 2016-11-04 | 2017-05-10 | 广州赛莱拉干细胞科技股份有限公司 | 培养基及其应用 |
CN106367387A (zh) * | 2016-11-04 | 2017-02-01 | 广州赛莱拉干细胞科技股份有限公司 | 培养基及其应用 |
CN108456657B (zh) * | 2018-03-31 | 2020-08-18 | 天津博雅秀岩生物技术有限公司 | 犬脐带间充质干细胞及其制备方法和冻存方法 |
TW202012618A (zh) * | 2018-04-12 | 2020-04-01 | 新加坡商細胞研究私人有限公司 | 一種誘導或改善間質幹細胞傷口癒合特性的方法 |
US20210301252A9 (en) * | 2018-04-12 | 2021-09-30 | Cellresearch Corporation Pte. Ltd. | Method of inducing or improving wound healing properties of mesenchymal stem cells |
CN108795853B (zh) * | 2018-05-28 | 2021-08-24 | 天津博雅秀岩生物技术有限公司 | 制备犬胎膜间充质干细胞的方法和犬胎膜间充质干细胞 |
CN108728408B (zh) * | 2018-05-28 | 2021-08-24 | 天津博雅秀岩生物技术有限公司 | 犬胎膜间充质干细胞及制备方法和使用的培养基 |
US20210254010A1 (en) * | 2018-06-14 | 2021-08-19 | Abraham J And Phyllis Katz Cord Blood Foundation | Isolation of Mesenchymal Stromal Cells |
CN108865987A (zh) * | 2018-07-20 | 2018-11-23 | 深圳市第二人民医院 | 一种人关节液间充质干细胞用的培养基及其制备方法 |
CN109432130A (zh) * | 2018-12-20 | 2019-03-08 | 中科广聚(北京)生物医学技术中心有限公司 | 间充质干细胞外泌体在制备预防和治疗放射性肺损伤的药物中的应用 |
CN110117527A (zh) * | 2019-05-15 | 2019-08-13 | 刘宝全 | 一种干细胞代谢废物的强化排出方法 |
CN110295140A (zh) * | 2019-06-04 | 2019-10-01 | 河北贝特赛奥生物科技有限公司 | 一种无血清培养骨髓间充质干细胞的方法 |
CN110373384A (zh) * | 2019-07-24 | 2019-10-25 | 安徽科门生物科技有限公司 | 一种无血清脂肪干细胞培养基及脂肪干细胞的培养方法 |
JP7348892B2 (ja) * | 2019-12-30 | 2023-09-21 | 佛教慈濟醫療財團法人 | 眼疾患を予防または治療する組成物及び方法 |
WO2022075294A1 (ja) * | 2020-10-07 | 2022-04-14 | 富士フイルム株式会社 | 関節治療用細胞製剤の製造方法、関節治療用細胞製剤および間葉系幹細胞の培養方法 |
CN113201492A (zh) * | 2021-06-22 | 2021-08-03 | 浙江三誉生物科技有限公司 | 一种骨髓间充质干细胞的培养基及培养方法 |
CN113999810B (zh) * | 2021-12-30 | 2022-04-26 | 北京赛尔富森生物科技有限公司 | 一种mrc-5细胞复苏培养液以及复苏方法 |
CN115372233B (zh) * | 2022-10-25 | 2023-03-24 | 华夏源(上海)生命科技有限公司 | 一种脂肪干细胞细胞周期的检测方法 |
CN118028229B (zh) * | 2024-04-11 | 2024-06-21 | 成都云测医学生物技术有限公司 | 一种从神经类器官获得间充质干细胞的制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5573937A (en) * | 1989-12-07 | 1996-11-12 | Snow Brand Milk Products Co., Ltd. | Serum free culture medium |
KR101037008B1 (ko) * | 2007-08-23 | 2011-05-25 | 주식회사 엘지화학 | 환형올레핀, 아크릴레이트 및 불포화 유기산을 포함하는공중합체, 및 이의 제조방법 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998004681A2 (en) * | 1996-07-25 | 1998-02-05 | Genzyme Corporation | Chondrocyte media formulations and culture procedures |
KR100679642B1 (ko) * | 2005-11-16 | 2007-02-06 | 주식회사 알앤엘바이오 | 인간 지방조직 유래 다분화능 줄기세포 및 이를 함유하는세포치료제 |
WO2007069813A1 (en) * | 2005-12-16 | 2007-06-21 | Modern Cell & Tissue Technologies Inc. | Methods for culturing mesenchymal stem cell and compositions comprising mesenchymal stem cell for reparing skin defects |
KR100908481B1 (ko) * | 2006-04-24 | 2009-07-21 | 코아스템(주) | 중간엽 줄기세포 배양 배지 및 이를 이용한 중간엽줄기세포의 배양 방법 |
JP2009540826A (ja) * | 2006-06-20 | 2009-11-26 | ジェンザイム・コーポレーション | 軟骨細胞増幅のための無血清培地およびその使用 |
KR101037002B1 (ko) | 2008-09-30 | 2011-05-25 | 세원셀론텍(주) | 연골세포 조기배양을 위한 연골세포 특이적 배양방법 |
KR101078419B1 (ko) * | 2009-03-20 | 2011-10-31 | 주식회사 스템메디언스 | 양수 내 태아 유래 중간엽줄기세포를 이용한 피부 상태개선용 조성물 |
CN102021143B (zh) * | 2010-11-24 | 2012-07-25 | 浙江大学 | 一种提高间充质干细胞迁移能力的预处理方法 |
-
2011
- 2011-08-31 KR KR1020110087498A patent/KR101138091B1/ko active IP Right Grant
- 2011-09-06 SI SI201131429T patent/SI2752484T1/en unknown
- 2011-09-06 PL PL11871607T patent/PL2752484T3/pl unknown
- 2011-09-06 EP EP11871607.5A patent/EP2752484B1/en active Active
- 2011-09-06 ES ES11871607.5T patent/ES2660898T3/es active Active
- 2011-09-06 CN CN201180073169.4A patent/CN103857789B/zh active Active
- 2011-09-06 HU HUE11871607A patent/HUE036910T2/hu unknown
- 2011-09-06 NO NO11871607A patent/NO2752484T3/no unknown
- 2011-09-06 WO PCT/KR2011/006582 patent/WO2013032052A1/ko active Application Filing
- 2011-09-06 PT PT118716075T patent/PT2752484T/pt unknown
- 2011-09-06 LT LTEP11871607.5T patent/LT2752484T/lt unknown
- 2011-09-06 US US14/241,393 patent/US9879226B2/en active Active
- 2011-09-06 DK DK11871607.5T patent/DK2752484T3/en active
- 2011-09-06 JP JP2014528250A patent/JP5872046B2/ja not_active Expired - Fee Related
- 2011-09-06 TR TR2018/02355T patent/TR201802355T4/tr unknown
-
2018
- 2018-02-13 HR HRP20180266TT patent/HRP20180266T1/hr unknown
- 2018-02-21 CY CY20181100198T patent/CY1119924T1/el unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5573937A (en) * | 1989-12-07 | 1996-11-12 | Snow Brand Milk Products Co., Ltd. | Serum free culture medium |
KR101037008B1 (ko) * | 2007-08-23 | 2011-05-25 | 주식회사 엘지화학 | 환형올레핀, 아크릴레이트 및 불포화 유기산을 포함하는공중합체, 및 이의 제조방법 |
Non-Patent Citations (2)
Title |
---|
GANG ET AL.: "In vitro mesengenic potential of human umbilical cord blood-derived mesenchymal stem cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 321, 2004, pages 102 - 108, XP004521404 * |
HILDEBRANDT ET AL.: "Influence of cell culture media conditions on the osteogenic differentiation of cord blood-derived mesenchymal stem cells", ANNALS OF ANATOMY, vol. 191, 2009, pages 23 - 32, XP025870120 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016027850A1 (ja) * | 2014-08-21 | 2016-02-25 | 味の素株式会社 | 間葉系幹細胞用培地 |
US10947508B2 (en) | 2014-08-21 | 2021-03-16 | Ajinomoto Co., Inc. | Culture medium for mesenchymal stem cells |
US10894947B1 (en) | 2016-04-29 | 2021-01-19 | Hope Biosciences, Llc | Method for generating protein rich conditioned medium |
US10959425B2 (en) | 2016-04-29 | 2021-03-30 | Hope Biosciences, Llc | Method of banking stem cells |
US10988731B2 (en) | 2016-04-29 | 2021-04-27 | Hope Biosciences, Llc | Formulation for storage, transportation, and delivery of protein rich conditioned medium |
US11111480B2 (en) | 2016-04-29 | 2021-09-07 | Hope Biosctences, Llc | Culture media for multipotent stem cells |
USD848022S1 (en) | 2017-07-14 | 2019-05-07 | Hope Biosciences, Llc | Container for storing biological material |
USD875967S1 (en) | 2017-07-14 | 2020-02-18 | Hope Biosciences, Llc | Container for storing biological material |
Also Published As
Publication number | Publication date |
---|---|
CY1119924T1 (el) | 2018-12-12 |
JP2014525262A (ja) | 2014-09-29 |
LT2752484T (lt) | 2018-03-12 |
EP2752484A4 (en) | 2015-04-15 |
NO2752484T3 (ko) | 2018-06-09 |
JP5872046B2 (ja) | 2016-03-01 |
CN103857789B (zh) | 2016-08-31 |
HRP20180266T1 (hr) | 2018-04-06 |
EP2752484A1 (en) | 2014-07-09 |
US20140370600A1 (en) | 2014-12-18 |
ES2660898T3 (es) | 2018-03-26 |
PL2752484T3 (pl) | 2018-06-29 |
DK2752484T3 (en) | 2018-03-05 |
KR101138091B1 (ko) | 2012-04-24 |
PT2752484T (pt) | 2018-03-01 |
HUE036910T2 (hu) | 2018-08-28 |
EP2752484B1 (en) | 2018-01-10 |
US9879226B2 (en) | 2018-01-30 |
SI2752484T1 (en) | 2018-04-30 |
CN103857789A (zh) | 2014-06-11 |
TR201802355T4 (tr) | 2018-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2013032052A1 (ko) | 중간엽 줄기세포 기본 배양 배지 조성방법, 중간엽 줄기세포 기본 배양 배지 및 이를 이용하여 배양분화된 세포치료제 | |
CN103060264B (zh) | 一种干细胞培养基及其应用和干细胞培养方法 | |
US10184112B2 (en) | Culture medium additive for use in serum-free culturing of animal cell, kit and use thereof | |
KR101022032B1 (ko) | 중간엽 줄기세포를 이용하여 모유두 조직을 제조하는 방법 | |
JP6148429B2 (ja) | ヒト多能性幹細胞の培養方法 | |
Lin et al. | Isolation and identification of mesenchymal stem cells from human lipoma tissue | |
EP3385372B1 (en) | Method for manufacturing mesenchymal cell line derived from vertebrate animal adipose tissue | |
JP2002529071A (ja) | 軟骨細胞様細胞のための無血清培地 | |
KR20060076781A (ko) | 세포 배양 배지 | |
US20230117670A1 (en) | Bioactive substance composition, serum-free medium comprising the composition, and uses thereof | |
TW200927927A (en) | Stem cell medium | |
WO2021254296A1 (zh) | 一种生物活性物质组合物、包含所述组合物的无血清培养基及其用途 | |
WO2012074265A2 (ko) | 줄기세포의 안정성 증진용 조성물 | |
WO2011105821A2 (ko) | 무혈청 줄기 세포 배양 조성물, 이를 함유한 조직 재생용 조성물 및 이를 이용한 조직 재생 방법 | |
AU756151B2 (en) | Immortalised cell lines derived from normal human skin tissues | |
WO2019103528A2 (ko) | 무혈청 배지 조성물 | |
WO2021225420A1 (ko) | 전능성 줄기세포로부터 중간엽 줄기세포를 분화시키는 방법 | |
WO2010008157A2 (ko) | 줄기세포의 외배엽성 세포로의 분화 방법 | |
JP2016073323A (ja) | ヒト多能性幹細胞の培養方法 | |
WO2018186649A1 (ko) | 역분화 줄기세포의 지속적인 계대배양을 통한 중간엽 줄기세포로의 분화방법 | |
WO2023065384A1 (zh) | 一种人间充质干细胞培养基 | |
WO2023158061A1 (ko) | 근육과 지방을 함께 분화시키는 배양육 제조방법 및 이로 제조된 배양육 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11871607 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011871607 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2014528250 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14241393 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |